Effect of Cyclooxygenase-2 Inhibition on Renal Function After Renal Ablation
Kidney failure is the common end of hypertension and renal diseases. Several authors have suggested that vasodilatory prostaglandins participate in the hemodynamic mechanism responsible for the development of kidney failure. However, the mechanism by which prostaglandins are increased in renal disea...
Gespeichert in:
Veröffentlicht in: | Hypertension (Dallas, Tex. 1979) Tex. 1979), 1999-10, Vol.34 (4, Part 2), p.848-853 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 853 |
---|---|
container_issue | 4, Part 2 |
container_start_page | 848 |
container_title | Hypertension (Dallas, Tex. 1979) |
container_volume | 34 |
creator | Sanchez, Pedro Lopez Salgado, Luis Miguel Ferreri, Nicholas R Escalante, Bruno |
description | Kidney failure is the common end of hypertension and renal diseases. Several authors have suggested that vasodilatory prostaglandins participate in the hemodynamic mechanism responsible for the development of kidney failure. However, the mechanism by which prostaglandins are increased in renal disease is not clear. Recently, 2 isoforms of the enzyme responsible for prostaglandin synthesis, cyclooxygenase, have been described as cyclooxygenase-1 (COX-1), a constitutive isoform, and cyclooxygenase-2 (COX-2), an inducible isoform. In the present study, we investigated whether COX-2-dependent prostaglandins participate in the evolution of renal functional changes after renal ablation. We inhibited prostaglandin synthesis by COX-1 and COX-2 with indomethacin (3 mg/kg) and prostaglandin synthesis by COX-2 with NS-398 (3 mg/kg) and tested the effect of these inhibitors on the renal functional changes elicited by renal ablation. Renal ablation produced an increase in urinary volume, protein, and prostaglandin E2, whereas urinary sodium and potassium were not affected and urinary osmolarity decreased; treatment with indomethacin or NS-398 partially prevented the renal functional changes elicited by renal ablation. Immunoblots for COX showed an increase in the expression of COX-2 protein 2 days after renal ablation. Furthermore, COX-2 mRNA expression was increased 1 day after renal ablation. These data suggest that COX-2-dependent prostaglandins participate in the renal mechanisms associated with the development of renal functional changes after renal ablation. |
doi_str_mv | 10.1161/01.hyp.34.4.848 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70853739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70853739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5426-716e45193be2f98b9a4ff4d10bebb40d7c93ef180a7f256e581e9760329b60f23</originalsourceid><addsrcrecordid>eNpdkNGLEzEQh4MoXj199k0WOXzbvUySzW4eS7nzDgqKKOhTSNKJ3TPd1GSXs_-9qS0ohpCQH99Mho-Q10AbAAnXFJrtYd9w0YimF_0TsoCWiVq0kj8lCwpK1Arg6wV5kfMDpSCE6J6TC6At47xjC7K-8R7dVEVfrQ4uxPjr8B1Hk7Fm1f24HewwDXGsyv5U4lDdzqP7kyz9hOkcLm0wx_AleeZNyPjqfF-SL7c3n1d39frD-_vVcl27VjBZdyBRtKC4ReZVb5UR3osNUIvWCrrpnOLooaem86yV2PaAqpOUM2Ul9YxfknenvvsUf86YJ70bssMQzIhxzrqjfcs7rgr49j_wIc6pjJw1KwpUmUEW6PoEuRRzTuj1Pg07kw4aqD5a1hT03bePmgstdLFcKt6c2852h5t_-JPWAlydAZOdCT6Z0Q35Lwe9ZOz4szhhjzEUm_lHmB8x6S2aMG01Lavo6mtQSkF5QF2OUvYbInySoA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>205291936</pqid></control><display><type>article</type><title>Effect of Cyclooxygenase-2 Inhibition on Renal Function After Renal Ablation</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Ovid Autoload</source><creator>Sanchez, Pedro Lopez ; Salgado, Luis Miguel ; Ferreri, Nicholas R ; Escalante, Bruno</creator><creatorcontrib>Sanchez, Pedro Lopez ; Salgado, Luis Miguel ; Ferreri, Nicholas R ; Escalante, Bruno</creatorcontrib><description>Kidney failure is the common end of hypertension and renal diseases. Several authors have suggested that vasodilatory prostaglandins participate in the hemodynamic mechanism responsible for the development of kidney failure. However, the mechanism by which prostaglandins are increased in renal disease is not clear. Recently, 2 isoforms of the enzyme responsible for prostaglandin synthesis, cyclooxygenase, have been described as cyclooxygenase-1 (COX-1), a constitutive isoform, and cyclooxygenase-2 (COX-2), an inducible isoform. In the present study, we investigated whether COX-2-dependent prostaglandins participate in the evolution of renal functional changes after renal ablation. We inhibited prostaglandin synthesis by COX-1 and COX-2 with indomethacin (3 mg/kg) and prostaglandin synthesis by COX-2 with NS-398 (3 mg/kg) and tested the effect of these inhibitors on the renal functional changes elicited by renal ablation. Renal ablation produced an increase in urinary volume, protein, and prostaglandin E2, whereas urinary sodium and potassium were not affected and urinary osmolarity decreased; treatment with indomethacin or NS-398 partially prevented the renal functional changes elicited by renal ablation. Immunoblots for COX showed an increase in the expression of COX-2 protein 2 days after renal ablation. Furthermore, COX-2 mRNA expression was increased 1 day after renal ablation. These data suggest that COX-2-dependent prostaglandins participate in the renal mechanisms associated with the development of renal functional changes after renal ablation.</description><identifier>ISSN: 0194-911X</identifier><identifier>EISSN: 1524-4563</identifier><identifier>DOI: 10.1161/01.hyp.34.4.848</identifier><identifier>PMID: 10523372</identifier><identifier>CODEN: HPRTDN</identifier><language>eng</language><publisher>Philadelphia, PA: American Heart Association, Inc</publisher><subject>Animals ; Biological and medical sciences ; Cyclooxygenase 1 ; Cyclooxygenase 2 ; Cyclooxygenase 2 Inhibitors ; Cyclooxygenase Inhibitors - pharmacology ; Cyclooxygenase Inhibitors - therapeutic use ; Dinoprostone - physiology ; Indomethacin - pharmacology ; Indomethacin - therapeutic use ; Isoenzymes - physiology ; Kidney Function Tests ; Male ; Medical sciences ; Membrane Proteins ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Nitrobenzenes - pharmacology ; Nitrobenzenes - therapeutic use ; Prostaglandin-Endoperoxide Synthases - physiology ; Rats ; Rats, Wistar ; Renal failure ; Renal Insufficiency - metabolism ; Renal Insufficiency - physiopathology ; Renal Insufficiency - prevention & control ; Sulfonamides - pharmacology ; Sulfonamides - therapeutic use</subject><ispartof>Hypertension (Dallas, Tex. 1979), 1999-10, Vol.34 (4, Part 2), p.848-853</ispartof><rights>1999 American Heart Association, Inc.</rights><rights>2000 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Oct 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5426-716e45193be2f98b9a4ff4d10bebb40d7c93ef180a7f256e581e9760329b60f23</citedby><cites>FETCH-LOGICAL-c5426-716e45193be2f98b9a4ff4d10bebb40d7c93ef180a7f256e581e9760329b60f23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,3687,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1186226$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10523372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanchez, Pedro Lopez</creatorcontrib><creatorcontrib>Salgado, Luis Miguel</creatorcontrib><creatorcontrib>Ferreri, Nicholas R</creatorcontrib><creatorcontrib>Escalante, Bruno</creatorcontrib><title>Effect of Cyclooxygenase-2 Inhibition on Renal Function After Renal Ablation</title><title>Hypertension (Dallas, Tex. 1979)</title><addtitle>Hypertension</addtitle><description>Kidney failure is the common end of hypertension and renal diseases. Several authors have suggested that vasodilatory prostaglandins participate in the hemodynamic mechanism responsible for the development of kidney failure. However, the mechanism by which prostaglandins are increased in renal disease is not clear. Recently, 2 isoforms of the enzyme responsible for prostaglandin synthesis, cyclooxygenase, have been described as cyclooxygenase-1 (COX-1), a constitutive isoform, and cyclooxygenase-2 (COX-2), an inducible isoform. In the present study, we investigated whether COX-2-dependent prostaglandins participate in the evolution of renal functional changes after renal ablation. We inhibited prostaglandin synthesis by COX-1 and COX-2 with indomethacin (3 mg/kg) and prostaglandin synthesis by COX-2 with NS-398 (3 mg/kg) and tested the effect of these inhibitors on the renal functional changes elicited by renal ablation. Renal ablation produced an increase in urinary volume, protein, and prostaglandin E2, whereas urinary sodium and potassium were not affected and urinary osmolarity decreased; treatment with indomethacin or NS-398 partially prevented the renal functional changes elicited by renal ablation. Immunoblots for COX showed an increase in the expression of COX-2 protein 2 days after renal ablation. Furthermore, COX-2 mRNA expression was increased 1 day after renal ablation. These data suggest that COX-2-dependent prostaglandins participate in the renal mechanisms associated with the development of renal functional changes after renal ablation.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cyclooxygenase 1</subject><subject>Cyclooxygenase 2</subject><subject>Cyclooxygenase 2 Inhibitors</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>Cyclooxygenase Inhibitors - therapeutic use</subject><subject>Dinoprostone - physiology</subject><subject>Indomethacin - pharmacology</subject><subject>Indomethacin - therapeutic use</subject><subject>Isoenzymes - physiology</subject><subject>Kidney Function Tests</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Proteins</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Nitrobenzenes - pharmacology</subject><subject>Nitrobenzenes - therapeutic use</subject><subject>Prostaglandin-Endoperoxide Synthases - physiology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Renal failure</subject><subject>Renal Insufficiency - metabolism</subject><subject>Renal Insufficiency - physiopathology</subject><subject>Renal Insufficiency - prevention & control</subject><subject>Sulfonamides - pharmacology</subject><subject>Sulfonamides - therapeutic use</subject><issn>0194-911X</issn><issn>1524-4563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkNGLEzEQh4MoXj199k0WOXzbvUySzW4eS7nzDgqKKOhTSNKJ3TPd1GSXs_-9qS0ohpCQH99Mho-Q10AbAAnXFJrtYd9w0YimF_0TsoCWiVq0kj8lCwpK1Arg6wV5kfMDpSCE6J6TC6At47xjC7K-8R7dVEVfrQ4uxPjr8B1Hk7Fm1f24HewwDXGsyv5U4lDdzqP7kyz9hOkcLm0wx_AleeZNyPjqfF-SL7c3n1d39frD-_vVcl27VjBZdyBRtKC4ReZVb5UR3osNUIvWCrrpnOLooaem86yV2PaAqpOUM2Ul9YxfknenvvsUf86YJ70bssMQzIhxzrqjfcs7rgr49j_wIc6pjJw1KwpUmUEW6PoEuRRzTuj1Pg07kw4aqD5a1hT03bePmgstdLFcKt6c2852h5t_-JPWAlydAZOdCT6Z0Q35Lwe9ZOz4szhhjzEUm_lHmB8x6S2aMG01Lavo6mtQSkF5QF2OUvYbInySoA</recordid><startdate>199910</startdate><enddate>199910</enddate><creator>Sanchez, Pedro Lopez</creator><creator>Salgado, Luis Miguel</creator><creator>Ferreri, Nicholas R</creator><creator>Escalante, Bruno</creator><general>American Heart Association, Inc</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>199910</creationdate><title>Effect of Cyclooxygenase-2 Inhibition on Renal Function After Renal Ablation</title><author>Sanchez, Pedro Lopez ; Salgado, Luis Miguel ; Ferreri, Nicholas R ; Escalante, Bruno</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5426-716e45193be2f98b9a4ff4d10bebb40d7c93ef180a7f256e581e9760329b60f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cyclooxygenase 1</topic><topic>Cyclooxygenase 2</topic><topic>Cyclooxygenase 2 Inhibitors</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>Cyclooxygenase Inhibitors - therapeutic use</topic><topic>Dinoprostone - physiology</topic><topic>Indomethacin - pharmacology</topic><topic>Indomethacin - therapeutic use</topic><topic>Isoenzymes - physiology</topic><topic>Kidney Function Tests</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Proteins</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Nitrobenzenes - pharmacology</topic><topic>Nitrobenzenes - therapeutic use</topic><topic>Prostaglandin-Endoperoxide Synthases - physiology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Renal failure</topic><topic>Renal Insufficiency - metabolism</topic><topic>Renal Insufficiency - physiopathology</topic><topic>Renal Insufficiency - prevention & control</topic><topic>Sulfonamides - pharmacology</topic><topic>Sulfonamides - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanchez, Pedro Lopez</creatorcontrib><creatorcontrib>Salgado, Luis Miguel</creatorcontrib><creatorcontrib>Ferreri, Nicholas R</creatorcontrib><creatorcontrib>Escalante, Bruno</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanchez, Pedro Lopez</au><au>Salgado, Luis Miguel</au><au>Ferreri, Nicholas R</au><au>Escalante, Bruno</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Cyclooxygenase-2 Inhibition on Renal Function After Renal Ablation</atitle><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle><addtitle>Hypertension</addtitle><date>1999-10</date><risdate>1999</risdate><volume>34</volume><issue>4, Part 2</issue><spage>848</spage><epage>853</epage><pages>848-853</pages><issn>0194-911X</issn><eissn>1524-4563</eissn><coden>HPRTDN</coden><abstract>Kidney failure is the common end of hypertension and renal diseases. Several authors have suggested that vasodilatory prostaglandins participate in the hemodynamic mechanism responsible for the development of kidney failure. However, the mechanism by which prostaglandins are increased in renal disease is not clear. Recently, 2 isoforms of the enzyme responsible for prostaglandin synthesis, cyclooxygenase, have been described as cyclooxygenase-1 (COX-1), a constitutive isoform, and cyclooxygenase-2 (COX-2), an inducible isoform. In the present study, we investigated whether COX-2-dependent prostaglandins participate in the evolution of renal functional changes after renal ablation. We inhibited prostaglandin synthesis by COX-1 and COX-2 with indomethacin (3 mg/kg) and prostaglandin synthesis by COX-2 with NS-398 (3 mg/kg) and tested the effect of these inhibitors on the renal functional changes elicited by renal ablation. Renal ablation produced an increase in urinary volume, protein, and prostaglandin E2, whereas urinary sodium and potassium were not affected and urinary osmolarity decreased; treatment with indomethacin or NS-398 partially prevented the renal functional changes elicited by renal ablation. Immunoblots for COX showed an increase in the expression of COX-2 protein 2 days after renal ablation. Furthermore, COX-2 mRNA expression was increased 1 day after renal ablation. These data suggest that COX-2-dependent prostaglandins participate in the renal mechanisms associated with the development of renal functional changes after renal ablation.</abstract><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>American Heart Association, Inc</pub><pmid>10523372</pmid><doi>10.1161/01.hyp.34.4.848</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0194-911X |
ispartof | Hypertension (Dallas, Tex. 1979), 1999-10, Vol.34 (4, Part 2), p.848-853 |
issn | 0194-911X 1524-4563 |
language | eng |
recordid | cdi_proquest_miscellaneous_70853739 |
source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Ovid Autoload |
subjects | Animals Biological and medical sciences Cyclooxygenase 1 Cyclooxygenase 2 Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors - pharmacology Cyclooxygenase Inhibitors - therapeutic use Dinoprostone - physiology Indomethacin - pharmacology Indomethacin - therapeutic use Isoenzymes - physiology Kidney Function Tests Male Medical sciences Membrane Proteins Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Nitrobenzenes - pharmacology Nitrobenzenes - therapeutic use Prostaglandin-Endoperoxide Synthases - physiology Rats Rats, Wistar Renal failure Renal Insufficiency - metabolism Renal Insufficiency - physiopathology Renal Insufficiency - prevention & control Sulfonamides - pharmacology Sulfonamides - therapeutic use |
title | Effect of Cyclooxygenase-2 Inhibition on Renal Function After Renal Ablation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A43%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Cyclooxygenase-2%20Inhibition%20on%20Renal%20Function%20After%20Renal%20Ablation&rft.jtitle=Hypertension%20(Dallas,%20Tex.%201979)&rft.au=Sanchez,%20Pedro%20Lopez&rft.date=1999-10&rft.volume=34&rft.issue=4,%20Part%202&rft.spage=848&rft.epage=853&rft.pages=848-853&rft.issn=0194-911X&rft.eissn=1524-4563&rft.coden=HPRTDN&rft_id=info:doi/10.1161/01.hyp.34.4.848&rft_dat=%3Cproquest_cross%3E70853739%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=205291936&rft_id=info:pmid/10523372&rfr_iscdi=true |